The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
Twist, which went public in October, reported that its revenues doubled this year due to increased sales of its synthetic DNA products and the introduction of NGS products.
Arbor will provide reagents to Tataa for its courses on next-generation sequencing applications, while Tataa will distribute Arbor's products in European countries.
